Anticancer drug sensitivity profiles of new and established melanoma cell lines.
about
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth.Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA.MITF and PAX3 Play Distinct Roles in Melanoma Cell Migration; Outline of a "Genetic Switch" Theory Involving MITF and PAX3 in Proliferative and Invasive Phenotypes of Melanoma.The role of the hippo pathway in melanocytes and melanoma.Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations
P2860
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@en
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@nl
type
label
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@en
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@nl
prefLabel
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@en
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@nl
P2093
P1433
P1476
Anticancer drug sensitivity profiles of new and established melanoma cell lines.
@en
P2093
Baguley BC
Holdaway KM
Marshall ES
Matthews JH
P304
P577
1993-01-01T00:00:00Z